RE:Need to clarify & very clearwhile you said this: Plain language, ONC has never eluded, suggested or indicated they would be doing a phase 3 trial alone.
onc said this in their nov. 9 pr: Oncolytics' collaborator, The Pancreatic Cancer Action Network (PanCAN), a pancreatic cancer patient advocacy organization, advised the company that it is implementing a strategic re-evaluation of the Precision PromiseSM program and will not be adding any new investigational therapies to the platform until the re-evaluation is complete. Oncolytics and PanCAN had previously planned to initiate a Phase 3 trial using the Precision PromiseSM platform in H1 2024. Oncolytics now plans to conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study and manage it directly within our Clinical Group and a contract research organization (CRO) with the goal of enrolling the first patient in mid-2024.
a CRO is a for-hire group, not a company which would be providing $ to onc. not sure about the reference to "our Clinical Group", but that kind of sounds like an in-house onc group.